VSTM
Verastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12c Mutant Non-Small Cell Lung Cancer
时间：2024-12-18 20:30:00 市场： 美股
Rpt-Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
时间：2024-11-07 06:09:52 市场： 美股 综合
Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
时间：2024-11-07 06:09:51 市场： 美股 综合
Verastem Oncology Announces Details for the Oral Presentation of the Mature Ramp 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the Igcs 2024 Annual Meeting
时间：2024-10-09 18:00:00 市场： 美股 综合
Verastem Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $13
时间：2024-09-30 18:34:00 市场： 美股 综合